Pivotal Phase III Trials to Evaluate Four Promising Agents in Merck's Oncology, Hematology Pipeline

Merck is actively enrolling patients across Phase III trials for four novel candidates for hematologic malignancies and solid tumors.

Source link
#Pivotal #Phase #III #Trials #Evaluate #Promising #Agents #Merck039s #Oncology #Hematology #Pipeline